Madrigal Pharmaceuticals
MDGL
125 hedge funds and large institutions have $1.27B invested in Madrigal Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 46 increasing their positions, 36 reducing their positions, and 11 closing their positions.
145% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 11
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
59% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $17.1M
28% more capital inflows, than outflows
Capital inflows: $92.8M | Capital outflows: $72.5M
28% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 36
15% more funds holding
Funds holding: 109 → 125 (+16)
1.09% more ownership
Funds ownership: 71.87% → 72.96% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.6M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$10.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.56M |
| 4 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.06M |
| 5 |
Two Sigma Investments
New York
|
+$5.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$20.1M |
| 2 |
Goldman Sachs
New York
|
-$9.57M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.28M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.71M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.27M |
MDGL Hedge Fund Activity: Q2 2020 in Review
125 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2020, worth a combined $1.27B — up 72% from $741M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new MDGL positions and 11 closed out — a net gain of 16 holders — while 46 added to existing stakes and 36 trimmed.
The largest buyer was State Street, adding an estimated $12.6M. The largest seller was HealthCor Management, cutting an estimated $20.1M.
- 125 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2020, up from 109 in Q1 2020.
- Funds reported $1.27B of Madrigal Pharmaceuticals stock for Q2 2020, up 72% quarter-over-quarter.
- 27 funds opened new Madrigal Pharmaceuticals positions in Q2 2020 and 11 closed out, a net change of +16 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2020 was State Street, an estimated $12.6M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2020 was HealthCor Management, an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2020.